A Study of IXAZOMIB in Adult Patients With Lymphoma

Phase 1 Completed 31 enrolled Millennium Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter, phase 1, dose-escalation study of IXAZOMIB in adult patients with lymphoma. This study will be the first to administer IXAZOMIB to patients with lymphoma.

Timeline

Start: 2009-08
Primary completion: 2014-10
Completion: 2014-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ixazomib	Unknown	0.125 mg/m2	Intravenous

A Study of IXAZOMIB in Adult Patients With Lymphoma

Summary

Timeline

Drugs

Indications